GlassScriptPhysician profile
Shadi E Oweis
NPI 1578697454
$4,507.46
in general payments reported to CMS, 2019-2025
33 companies · $730 in 2025
The $730 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $558 · 2020: $42.03 · 2021: $307 · 2022: $743 · 2023: $1,208 · 2024: $920 · 2025: $730.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,844 · Education: $13.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,843.95 |
| Education | $13.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $417.40 | 2019-2025 | Tavneos, Krystexxa, Evenity |
| Travere Therapeutics, INC. | $366.02 | 2023-2025 | |
| Aurinia Pharma U.S., INC. | $358.51 | 2021-2024 | Lupkynis |
| Bayer Healthcare Pharmaceuticals INC. | $333.07 | 2022-2024 | |
| Astrazeneca Pharmaceuticals LP | $322.32 | 2019-2025 | Lokelma, Farxiga |
| Calliditas Therapeutics US INC. | $282.18 | 2023-2025 | Tarpeyo |
| Horizon Therapeutics Plc | $251.08 | 2019-2023 | Krystexxa |
| Vifor Pharma, INC. | $250.96 | 2021-2025 | Veltassa |
| Otsuka America Pharmaceutical, INC. | $231.61 | 2019-2024 | Jynarque |
| Opko Pharmaceuticals, LLC | $219.42 | 2019-2025 | Rayaldee |
| Lilly USA, LLC | $216.54 | 2019-2025 | Jardiance |
| Baxter Healthcare | $186.42 | 2019-2023 | Renal - Pd |
| Novartis Pharmaceuticals Corporation | $145.20 | 2023-2025 | |
| Akebia Therapeutics INC | $132.46 | 2022-2025 | Vafseo |
| Glaxosmithkline, LLC. | $109.40 | 2021-2024 | Jesduvroq, Benlysta |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bard Peripheral Vascular, INC. | $96.79 | 2019 | |
| Inari Medical, INC. | $94.14 | 2022 | |
| Alexion Pharmaceuticals, INC. | $68.70 | 2022-2025 | Ultomiris |
| Vantive US Healthcare LLC | $56.46 | 2025 | Renal - Pd |
| Mallinckrodt Hospital Products INC. | $54.91 | 2022-2023 | Terlivaz |
| Cormedix INC. | $46.18 | 2024 | Defencath |
| Fresenius USA Marketing, INC. | $35.88 | 2023-2025 | Velphoro, Velphoro |
| Pfizer INC. | $34.53 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.56 | 2022 | |
| Cook Medical LLC | $25.73 | 2022 | |
| Cardiovascular Systems INC. | $24.37 | 2022 | |
| Kyowa Kirin, INC. | $22.39 | 2025 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $21.50 | 2025 | |
| Apellis Pharmaceuticals, INC. | $18.98 | 2025 | Empaveli |
| Scpharmaceuticals INC. | $14.28 | 2024 | |
| Ultragenyx Pharmaceutical INC. | $13.83 | 2021 | |
| Janssen Pharmaceuticals, INC | $13.52 | 2019 | |
| Abbott Laboratories | $13.12 | 2023 | Diamondback Peripheral |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shadi Oweis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.